Evaluating the role of FAMIly history of cancer and diagnosis of multiple neoplasms in cancer patients receiving PD-1/PD-L1 checkpoint inhibitors. the multicenter FAMI-L1 study
| Autor: | Fabiana Perrone, Rosa Rita Silva, Cristina Zannori, Paolo Marchetti, Francesco Atzori, Giampiero Porzio, Raffaele Giusti, Domenico Mallardo, Nicola Tinari, Enzo Veltri, Tea Zeppola, Federica De Galitiis, Marcello Tiseo, Alessio Cortellini, Cecilia Anesi, Claudia Mosillo, Alessandro Inno, Marianna Tudini, Stefania Gori, Alain Gelibter, Marco Filetti, Corrado Ficorella, Alessandra Tessitore, Melissa Bersanelli, Andrea Botticelli, Mario Occhipinti, Antonino Grassadonia, Marco Russano, Maria Giuseppa Vitale, Annagrazia Pireddu, Maria Concetta Fargnoli, Francesco Malorgio, Katia Cannita, Federica Pergolesi, Silvia Rinaldi, Michele De Tursi, Maria Rita Migliorino, Francesca Rastelli, Daniela Iacono, Gian Carlo Antonini Cappellini, Rossana Berardi, Pietro Di Marino, Alessandro Parisi, Sergio Bracarda, Paolo A. Ascierto, Daniele Santini, Sebastiano Buti, Federica Zoratto, Francesco Martella |
|---|---|
| Jazyk: | angličtina |
| Rok vydání: | 2020 |
| Předmět: |
0301 basic medicine
Oncology multiple neoplasms medicine.medical_specialty Multivariate analysis medicine.medical_treatment Immunology Programmed Cell Death 1 Receptor ddr genes B7-H1 Antigen family history of cancer immune checkpoint inhibitors 03 medical and health sciences 0302 clinical medicine Antineoplastic Agents Immunological Internal medicine Neoplasms medicine Immunology and Allergy Humans cardiovascular diseases Family history Adverse effect RC254-282 Retrospective Studies Original Research business.industry Incidence (epidemiology) Hazard ratio pd-1 Cancer Neoplasms. Tumors. Oncology. Including cancer and carcinogens Retrospective cohort study Immunotherapy RC581-607 medicine.disease immunotherapy 030104 developmental biology 030220 oncology & carcinogenesis Immunologic diseases. Allergy business |
| Zdroj: | OncoImmunology, Vol 9, Iss 1 (2020) Oncoimmunology |
| Popis: | Background: We investigate the role of family history of cancer (FHC) and diagnosis of metachronous and/or synchronous multiple neoplasms (MN), during anti-PD-1/PD-L1 immunotherapy. Design: This was a multicenter retrospective study of advanced cancer patients treated with anti-PD-1/PD-L1 immunotherapy. FHC was collected in lineal and collateral lines, and patients were categorized as follows: FHC-high (in case of cancer diagnoses in both the lineal and collateral family lines), FHC-low (in case of cancer diagnoses in only one family line), and FHC-negative. Patients were also categorized according to the diagnosis of MN as follows: MN-high (>2 malignancies), MN-low (two malignancies), and MN-negative. Objective response rate (ORR), progression-free survival (PFS), overall survival (OS), and incidence of immune-related adverse events (irAEs) of any grade were evaluated. Results: 822 consecutive patients were evaluated. 458 patients (55.7%) were FHC-negative, 289 (35.2%) were FHC-low, and 75 (9.1%) FHC-high, respectively. 29 (3.5%) had a diagnosis of synchronous MN and 94 (11.4%) of metachronous MN. 108 (13.2%) and 15 (1.8%) patients were MN-low and MN-high, respectively. The median follow-up was 15.6 months. No significant differences were found regarding ORR among subgroups. FHC-high patients had a significantly longer PFS (hazard ratio [HR] = 0.69 [95% CI: 0.48–0.97], p = .0379) and OS (HR = 0.61 [95% CI: 0.39–0.93], p = .0210), when compared to FHC-negative patients. FHC-high was confirmed as an independent predictor for PFS and OS at multivariate analysis. No significant differences were found according to MN categories. FHC-high patients had a significantly higher incidence of irAEs of any grade, compared to FHC-negative patients (p = .0012). Conclusions: FHC-high patients seem to benefit more than FHC-negative patients from anti-PD-1/PD-L1 checkpoint inhibitors. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|